Protective effects of intracellular reactive oxygen species generated by 6-formylpterin on tumor necrosis factor-alpha-induced apoptotic cell injury in cultured rat hepatocytes. 2005

Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
Department of Anesthesia, Kyoto University Hospital, Kyoto 606-8507, Japan.

The effects of 6-formylpterin on tumor necrosis factor (TNF)-alpha-induced apoptotic cell injury were studied in cultured rat hepatocytes. The incubation of the hepatocytes with TNF-alpha and actinomycin D (ActD) induced the apoptotic cell injury. The level of aspartate transaminase (AST) in the culture supernatant increased, and the cell viability, estimated by mitochondrial respiration (MTT assay), decreased. The DNA fragmentation and the caspase 3-like activity, which are characterized to apoptosis, increased. When the hepatocytes were incubated with 100-500 microM 6-formylpterin, the intracellular formation of reactive oxygen species (ROS) was observed, and the ratio of reduced and oxidized glutathione (GSH/GSSG) of whole cell lysate decreased. The co-incubation of the TNF-alpha/ActD-treated hepatocytes with 100-500 microM 6-formylpterin attenuated the TNF-alpha/ActD-induced apoptotic cell injury. The level of AST decreased and the cell viability increased. Both the DNA fragmentation and the caspase 3-like activity decreased. The caspases, executors of apoptosis, are known to require a reduced cystein in their active site to function, and the intact intracellular GSH/GSSG is essential for the caspase activation. Therefore, our findings suggest that intracellular ROS generated by 6-formylpterin decline the intracellular redox state to an oxidant state, which suppresses the caspase activity and prevents the apoptotic cell injury of hepatocytes.

UI MeSH Term Description Entries
D008297 Male Males
D008930 Mitochondria, Liver Mitochondria in hepatocytes. As in all mitochondria, there are an outer membrane and an inner membrane, together creating two separate mitochondrial compartments: the internal matrix space and a much narrower intermembrane space. In the liver mitochondrion, an estimated 67% of the total mitochondrial proteins is located in the matrix. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p343-4) Liver Mitochondria,Liver Mitochondrion,Mitochondrion, Liver
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D011622 Pterins Compounds based on 2-amino-4-hydroxypteridine. Pterin
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic

Related Publications

Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
May 2005, Apoptosis : an international journal on programmed cell death,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
May 1995, Toxicology,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
June 2003, Journal of hepatology,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
November 2008, Current hypertension reviews,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
November 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
September 2015, Biochemical and biophysical research communications,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
January 2003, Drugs under experimental and clinical research,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
June 2005, Collegium antropologicum,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
December 2006, Biochemical and biophysical research communications,
Hisanari Ishii, and Toshiyuki Arai, and Hiroko Mori, and Hiroko Yamada, and Nobuyuki Endo, and Keisuke Makino, and Kazuhiko Fukuda
January 2018, The Journal of toxicological sciences,
Copied contents to your clipboard!